Aclaris Therapeutics Inc [NASDAQ: ACRS] price surged by 53.17 percent to reach at $1.09.
The one-year ACRS stock forecast points to a potential downside of -25.6. The average equity rating for ACRS stock is currently 3.00, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Guru’s Opinion on Aclaris Therapeutics Inc [ACRS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ACRS shares is $2.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ACRS stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Aclaris Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on Nov-19-24. The new note on the price target was released on January 22, 2024, representing the official price target for Aclaris Therapeutics Inc stock.
The Average True Range (ATR) for Aclaris Therapeutics Inc is set at 0.30, with the Price to Sales ratio for ACRS stock in the period of the last 12 months amounting to 7.79. The Price to Book ratio for the last quarter was 1.72, with the Price to Cash per share for the same quarter was set at 1.90.
ACRS Stock Performance Analysis:
Aclaris Therapeutics Inc [ACRS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 19.39. With this latest performance, ACRS shares gained by 163.87% in over the last four-week period, additionally plugging by 163.87% over the last 6 months – not to mention a rise of 254.72% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACRS stock in for the last two-week period is set at 76.30, with the RSI for the last a single of trading hit 76.21, and the three-weeks RSI is set at 76.08 for Aclaris Therapeutics Inc [ACRS]. The present Moving Average for the last 50 days of trading for this stock 1.53, while it was recorded at 2.47 for the last single week of trading, and 1.29 for the last 200 days.
Insight into Aclaris Therapeutics Inc Fundamentals:
Aclaris Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.03 and a Current Ratio set at 7.03.
ACRS Stock EPS
With the latest financial reports released by the company, Aclaris Therapeutics Inc posted -0.02/share EPS, while the average EPS was predicted by analysts to be reported at -0.39/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.37. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ACRS.
Aclaris Therapeutics Inc [ACRS] Institutonal Ownership Details
There are presently around $73.55%, or 75.56%% of ACRS stock, in the hands of institutional investors. The top three institutional holders of ACRS stocks are: BML CAPITAL MANAGEMENT, LLC with ownership of 12.99 million shares, which is approximately 18.2739%. VANGUARD GROUP INC, holding 4.69 million shares of the stock with an approximate value of $$5.16 million in ACRS stocks shares; and VANGUARD GROUP INC, currently with $$3.67 million in ACRS stock with ownership which is approximately 4.6948%.
